Actively Recruiting
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Led by Breast International Group · Updated on 2025-07-16
1000
Participants Needed
52
Research Sites
882 weeks
Total Duration
On this page
Sponsors
B
Breast International Group
Lead Sponsor
J
Jules Bordet Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patients are those who are 18 or older, either female or male, and who have not received more than 1 type of treatment from the time metastases were discovered, metastasi(e)s has just been diagnosed or their disease has come back (disease relapse). Biopsy samples from both the primary and metastatic (or relapsed) tumor will be collected for central analyses, together with blood, serum and plasma samples. Any samples not analyzed immediately will be stored in an independent bio-repository to enable future (not yet defined) research aimed at better understanding metastatic breast cancer. In summary, the main objectives of AURORA are to better understand the genetic aberrations in metastatic breast cancer and to discover the mechanisms of response or resistance to therapy, in order to ultimately identify the "right therapy for each individual patient". At the same time, patients with genetic aberrations that are being targeted by new drugs in development will be offered the possibility to participate in clinical trials, when approved and available in their countries. Ultimately, the aim of AURORA is to improve the outcomes of all patients diagnosed with metastatic breast cancer.
CONDITIONS
Official Title
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female or male 18 years or older with locally recurrent/advanced breast cancer not curable or metastatic breast cancer
- No more than one line of systemic therapy in the metastatic setting
- Histopathology-confirmed triple-negative breast cancer or invasive lobular carcinoma eligible under protocol 4.0
- Late relapse breast cancer defined as relapse more than 10 years after primary diagnosis
- Written informed consent provided
- ECOG Performance Status of 0 or 1
- Availability of primary tumor tissue for research
- Metastatic lesion accessible for biopsy and agreement with biopsy procedure
- Biopsy performed before starting first or second line systemic therapy
- Availability of blood, serum, and plasma samples at screening
- Agreement to provide blood samples regularly during follow-up
You will not qualify if you...
- More than one line of systemic therapy received in metastatic setting
- Prior palliative radiotherapy to the only biopsy-accessible site
- Severe blood, kidney, or liver dysfunction including albumin less than 3 g/dl
- Increased risk of bleeding during biopsy as judged by physician
- Other malignancies within last 5 years except treated in situ cervical carcinoma or treated basal/squamous cell skin carcinoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 52 locations
1
Institut Jules Bordet
Brussels, Belgium, 1000
Actively Recruiting
2
Cliniques Universitaires St-Luc
Brussels, Belgium, 1200
Actively Recruiting
3
Grand Hopital Charleroi
Charleroi, Belgium, 6000
Actively Recruiting
4
UZ Leuven
Leuven, Belgium, 3000
Actively Recruiting
5
CHU de Liège
Liège, Belgium, 4000
Active, Not Recruiting
6
Clinique et Maternité Sainte-Elisabeth (CMSE - Namur)
Namur, Belgium, 5000
Actively Recruiting
7
Kliniken Essen-Mitte, Klinik für Senologie/ Brustzentrum
Essen, Germany, 45136
Completed
8
Frauenkliniken Maistrasse-Innenstadt und Großhadern
München, Germany, 80336
Active, Not Recruiting
9
Landspitali
Reykjavik, Iceland, 101
Active, Not Recruiting
10
Ospedale degli Infermi - S.O.C.Oncologia
Biella, Italy
Completed
11
Ospedale di Bolzano - Oncologia Medica
Bolzano, Italy, 39100
Active, Not Recruiting
12
Ospedale Ramazzini di Carpi
Carpi, Italy
Active, Not Recruiting
13
IRCCS AOU San Martino-IST
Genova, Italy, 16132
Active, Not Recruiting
14
ULSS 21 Legnago
Legnago, Italy, 37045
Active, Not Recruiting
15
Istituto Europeo di Oncologia
Milan, Italy, 20141
Active, Not Recruiting
16
UOC Oncologia Medica - AOU Parma
Parma, Italy, 43126
Active, Not Recruiting
17
Fondazione Salvatore Maugeri
Pavia, Italy
Completed
18
IRCCS Az Ospedaliera S.Maria Nuova
Reggio Emilia, Italy
Active, Not Recruiting
19
Centre Hospitalier
Luxembourg, Luxembourg, 1210
Active, Not Recruiting
20
Champalimaud Foundation
Lisbon, Portugal, 1400-038
Actively Recruiting
21
Complexo Hospitalario Universitario A Coruña
A Coruña, Spain, 15006
Actively Recruiting
22
Hospital del Mar
Barcelona, Spain, 08003
Actively Recruiting
23
Dr Rosell Oncology Institute, Quirón Dexeus University Hospital
Barcelona, Spain, 08028
Active, Not Recruiting
24
Hospital Vall d'Hebron
Barcelona, Spain, 08035
Active, Not Recruiting
25
Consorcio Hospitalario Provincial de Castellón
Castellon, Spain, 12002
Completed
26
Hospital San Pedro de Alcantara
Cáceres, Spain, 10003
Active, Not Recruiting
27
Hospital Universitari Arnau de Vilanova
Lleida, Spain, 25198
Active, Not Recruiting
28
MD Anderson Cancer Center
Madrid, Spain, 28033
Active, Not Recruiting
29
Hospital Clínico San Carlos
Madrid, Spain, 28040
Actively Recruiting
30
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Active, Not Recruiting
31
Centro Integral Oncológico Clara Campa
Madrid, Spain, 28050
Active, Not Recruiting
32
Hospital Universitario Virgen del Rocio
Seville, Spain, 41013
Completed
33
Instituto Valenciano de Oncología
Valencia, Spain, 46009
Actively Recruiting
34
Hospital Clinico Universitario de Valencia
Valencia, Spain, 46010
Active, Not Recruiting
35
Hospital General Universitario de Valencia
Valencia, Spain, 46014
Completed
36
Sahlgrenska University Hospital
Gothenburg, Sweden
Active, Not Recruiting
37
Ryhov County Hospital
Jönköping, Sweden, 55185
Active, Not Recruiting
38
Kantonsspital Baden
Baden, Switzerland
Completed
39
Inselspital Bern
Bern, Switzerland
Completed
40
Kantonsspital Graubuenden
Chur, Switzerland
Completed
41
Luzerner Kantonsspital, Division of Medical Oncology
Lucerne, Switzerland, 6003
Completed
42
Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom, B15 2TH
Active, Not Recruiting
43
University Hospitals Bristol NHS Foundation Trust
Bristol, United Kingdom, BS2 8HW
Active, Not Recruiting
44
Velindre NHS Trust
Cardiff, United Kingdom, CF15 7QZ
Active, Not Recruiting
45
NHS Tayside, Ninewells Hospital
Dundee, United Kingdom, DD1 9SY
Active, Not Recruiting
46
Edinburgh Cancer Centre - Western General Hospital
Edinburgh, United Kingdom, EH4 2XU
Active, Not Recruiting
47
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom, G12 0YN
Active, Not Recruiting
48
Christie NHS Foundation Trust
Manchester, United Kingdom
Active, Not Recruiting
49
Nottingham University Hospital NHS Trust
Nottingham, United Kingdom
Active, Not Recruiting
50
Singleton Hospital - ABM University Health Board
Swansea, United Kingdom, SA2 8QA
Active, Not Recruiting
51
Royal Cornwall Hospital - Royal Cornwall Hospitals NHS Trust
Truro, United Kingdom, TR1 3LJ
Active, Not Recruiting
52
Yeovil District Hospital NHS Foundation Trust
Yeovil, United Kingdom, BA21 4AT
Active, Not Recruiting
Research Team
A
AURORA BIG HQ
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here